Sanofi's Kumar On Drug Pricing And US Election Rhetoric
This article was originally published in Scrip
Executive Summary
Suresh Kumar, member of Sanofi's executive committee and executive vice president, external affairs, says that part of the high octane discussion in the US around drug pricing in the run up to the presidential election is "populist" but there's another part that stakeholders need to address.